Enzalutamide
- Generic Name
- Enzalutamide
- Brand Names
- Xtandi, Enzalutamide Viatris
- Drug Type
- Small Molecule
- Chemical Formula
- C21H16F4N4O2S
- CAS Number
- 915087-33-1
- Unique Ingredient Identifier
- 93T0T9GKNU
- Background
Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012. Although androgen deprivation therapy (ADT) is the first-line treatment of prostate cancer and remission can be achieve...
- Indication
Enzalutamide is indicated for the treatment of castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer (mCRPC). It is also used in combination with talazoparib for the treatment of adult patients with HRR gene-mutated mCRPC.
- Associated Conditions
- Castration Resistant Prostate Cancer, Metastatic Castration Sensitive Prostate Cancer (mCSPC), Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Associated Therapies
- -
Enzalutamide in Combination With Gemcitabine and Nab-Paclitaxel for the Treatment of Advanced Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-05-14
- Last Posted Date
- 2021-08-17
- Target Recruit Count
- 25
- Registration Number
- NCT02138383
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Enzalutamide Plus Everolimus in Men With Metastatic Castrate-Resistant Prostate Cancer
- First Posted Date
- 2014-04-29
- Last Posted Date
- 2021-05-04
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 38
- Registration Number
- NCT02125084
- Locations
- 🇺🇸
Tennessee Oncology, Chattanooga, Tennessee, United States
🇺🇸Tennessee Oncology PLLC, Nashville, Tennessee, United States
🇺🇸Florida Cancer Specialists, Fort Myers, Florida, United States
Sequencing Abiraterone and Enzalutamide in mCRPC
- Conditions
- Interventions
- First Posted Date
- 2014-04-29
- Last Posted Date
- 2020-08-07
- Lead Sponsor
- British Columbia Cancer Agency
- Target Recruit Count
- 202
- Registration Number
- NCT02125357
- Locations
- 🇨🇦
BC Cancer Agency - Vancouver Centre, Vancouver, British Columbia, Canada
🇨🇦BC Cancer Agency - Southern Interior, Kelowna, British Columbia, Canada
🇨🇦Vancouver Prostate Centre, Vancouver, British Columbia, Canada
A Study to Monitor the Safety of Enzalutamide in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2014-04-28
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 30
- Registration Number
- NCT02124668
- Locations
- 🇬🇪
Site GE99502, Tbilisi, Georgia
🇷🇺Site RU70002, Moscow, Russian Federation
🇷🇺Site RU70003, Moscow, Russian Federation
A Study to Evaluate Enzalutamide After Abiraterone in Metastatic Castration-Resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-04-17
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 215
- Registration Number
- NCT02116582
- Locations
- 🇩🇪
Site DE49005, Nuertingen, Baden-Wuerttemberg, Germany
🇬🇧Site GB44004, Birmingham, United Kingdom
🇧🇪Site BE32001, Brussels, Flemish Brabant, Belgium
Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy
- Conditions
- Interventions
- First Posted Date
- 2014-03-31
- Last Posted Date
- 2024-03-22
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 36
- Registration Number
- NCT02099864
- Locations
- 🇺🇸
UCSF Medical Center-Mount Zion, San Francisco, California, United States
🇺🇸OHSU Knight Cancer Institute, Portland, Oregon, United States
A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) Metastatic or Locally Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-03-19
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 103
- Registration Number
- NCT02091960
- Locations
- 🇨🇦
Site CA15026, Saskatoon, Saskatchewan, Canada
🇨🇦Site CA15001, Quebec, Canada
🇮🇹Site IT39003, Milan, Italy
RE-sensitizing With Supraphysiologic Testosterone to Overcome REsistance (The RESTORE Study)
- Conditions
- Interventions
- First Posted Date
- 2014-03-18
- Last Posted Date
- 2022-06-27
- Target Recruit Count
- 112
- Registration Number
- NCT02090114
- Locations
- 🇺🇸
Sibley Memorial Hospital, Washington, District of Columbia, United States
🇺🇸The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
Enzalutamide and Hormone Therapy Before, During, and After Radiation for High Risk Localized Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-02-17
- Last Posted Date
- 2020-10-12
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 7
- Registration Number
- NCT02064582
- Locations
- 🇺🇸
UT Southwestern Medical Center, Dallas, Texas, United States
LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Hormone Sensitive Prostate Cancer
- First Posted Date
- 2014-02-10
- Last Posted Date
- 2023-05-10
- Lead Sponsor
- Barbara Ann Karmanos Cancer Institute
- Target Recruit Count
- 71
- Registration Number
- NCT02058706
- Locations
- 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Henry Ford Hospital, Detroit, Michigan, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.